Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

KIZ OpenIR > 科研部门 > 肿瘤生物学（陈策实）

	Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
	Dong, C; Wu, J; Chen, Y; Nie, JN; Chen, CS
	2021
发表期刊	FRONTIERS IN PHARMACOLOGY
卷号	12
摘要	Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of drugs targeting PI3K/AKT/mTOR are being investigated in clinical trials by combining them with standard therapies to overcome acquired resistance in breast cancer. In this review, we summarize the critical role of the PI3K/AKT/mTOR pathway in drug resistance, the development of PI3K/AKT/mTOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer.
收录类别	sci
语种	英语
文献类型	期刊论文
条目标识符	http://ir.kiz.ac.cn/handle/152453/13673
专题	科研部门_肿瘤生物学（陈策实）
推荐引用方式 GB/T 7714	Dong, C,Wu, J,Chen, Y,et al. Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer[J]. FRONTIERS IN PHARMACOLOGY,2021,12.
APA	Dong, C,Wu, J,Chen, Y,Nie, JN,&Chen, CS.(2021).Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.FRONTIERS IN PHARMACOLOGY,12.
MLA	Dong, C,et al."Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer".FRONTIERS IN PHARMACOLOGY 12(2021).

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
2023032913.pdf（1669KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	请求全文